In a long-term North Karelia study of 3,539 adults with type 2 diabetes followed through 2024, patients with decreasing BMI showed room for closer follow-up: they had the lowest HbA1c and LDL cholesterol monitoring, even as healthcare utilization was highest. The study also found distinct BMI trajectories after diagnosis—stable (77.7%), increasing (14.6%), and decreasing (7.7%)—with different comorbidity and medication patterns across groups.

Why It Matters To Your Practice

• NPs and PAs are often the clinicians most likely to spot trajectory changes early, especially when weight loss looks encouraging on the surface but may mask gaps in metabolic monitoring.

• Patients in the decreasing BMI group had less HbA1c and LDL measurement activity, suggesting frontline teams may need to tighten lab follow-up even when BMI trends appear favorable.

• The increasing BMI group showed heavier accumulation of chronic kidney and urinary tract disease, obesity-related diagnoses, sleep disorders, and chronic lower respiratory diseases.

Clinical Benefits

• Tracking BMI trajectory—not just a single BMI value—can help you identify which patients need more proactive outreach, lab reminders, and treatment review.

• The stable group made up most patients (77.7%), while smaller increasing and decreasing groups may deserve more individualized care plans.

• GLP-1 agonist use differed over time by trajectory class, reinforcing the value of medication reconciliation and longitudinal treatment planning in primary care.

Managing Risks

• Do not assume falling BMI means lower risk: in this study, the decreasing group had the highest healthcare utilization and higher prevalence of dementia plus cardiovascular and pulmonary diseases.

• For patients with rising BMI, consider closer surveillance for renal, urinary, respiratory, and obesity-linked complications.

• Targeted support for metabolic control, comorbidity review, and repeat lab monitoring may help prevent patients from slipping through the cracks between visits.

The Bottom Line

• This study suggests BMI change after T2D diagnosis is a practical risk signal, and NPs and PAs are in prime position to act on it before missed monitoring becomes missed disease control.

• Your frontline judgment is not secondary—it is central to catching the patients whose weight trend, lab follow-up, and comorbidity burden are moving in different directions.